Voyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $30.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 247.62% from the stock's current price.

Other analysts also recently issued reports about the company. Wedbush lowered their price objective on Voyager Therapeutics from $10.00 to $8.00 and set a "neutral" rating for the company in a research note on Tuesday. Citigroup began coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They set a "buy" rating and a $16.00 price objective on the stock. Guggenheim assumed coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They set a "buy" rating and a $22.00 price objective on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Monday. Finally, Oppenheimer restated an "outperform" rating and set a $18.00 price target on shares of Voyager Therapeutics in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Voyager Therapeutics Stock Up 0.7 %

VYGR stock traded up $0.06 during midday trading on Thursday, reaching $8.63. 529,825 shares of the company's stock traded hands, compared to its average volume of 838,477. The firm's fifty day moving average price is $8.77 and its 200-day moving average price is $8.09. Voyager Therapeutics has a 52 week low of $6.06 and a 52 week high of $14.34. The company has a market cap of $469.39 million, a price-to-earnings ratio of -172.57 and a beta of 0.98.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.49%. The firm had revenue of $90.06 million during the quarter, compared to analysts' expectations of $4.95 million. Analysts forecast that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Gladius Capital Management LP bought a new position in shares of Voyager Therapeutics during the 3rd quarter valued at approximately $25,000. Ameritas Investment Partners Inc. grew its holdings in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock valued at $37,000 after purchasing an additional 1,300 shares during the period. AJOVista LLC purchased a new stake in Voyager Therapeutics in the fourth quarter worth $39,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $43,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Voyager Therapeutics by 302.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,399 shares of the company's stock valued at $54,000 after buying an additional 4,809 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.